PDF电子书：Synthetic Messenger RNA and Cell Metabolism Modulation (Springer MMB-

xyklmu

, C; n# s" U6 p9 @  P/ q- w! n8 R7 [6 Z% a0 Q" N: R
[hide][/hide]; N) R  z( `7 o' v. t4 \. n( m: ?
) q8 O1 K7 h- \3 B7 B. C+ I& J0 m
$ U6 l$ E- {6 X5 f9 L* l
Synthetic Messenger RNA
5 D' C1 V( N/ e; c2 k$ t: d% Cand Cell Metabolism Modulation0 n3 b+ ~6 l8 K1 d1 m# S: {
Methods and Protocols
) f8 h* q. h+ m( a3 T0 iEdited by2 z% A8 U+ g8 s8 z0 c. E
Peter M. Rabinovich; N% Y3 [) }  u# _' H2 m
Department of Genetics, The Anlyan Center, Yale School of Medicine,2 S7 B, V$ c  k2 P, V, H- L2 @8 B' v
New Haven, Connecticut, USA- a, u$ z1 Q. F) ~" M+ \: D  F
5 o1 _9 a+ v! w. n

0 t; |- t; ~( ?0 B& iContents$ B8 v( E$ C) ?, F) j# D
Preface. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . v
4 D* c  Z9 K: b6 K" l% V/ y1 ?  w' [Contributors. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ix0 Y) U5 l) W( L: @6 I0 z" k
PART I mRNA SYNTHESIS, PURI FI CATION, AND TRANSFER
7 X' U; a- Y& s! e1 Cell Engineering with Synthetic Messenger RNA . . . . . . . . . . . . . . . . . . . . . . 32 o; A' o  [- x
Peter M. Rabinovich and Sherman M. Weissman, W& y6 T+ H# _5 ^
2 In Vitro Transcription of Long RNA Containing Modified Nucleosides . . . . . 291 x- b: e' m$ V  [, V
Norbert Pardi, Hiromi Muramatsu, Drew Weissman, and Katalin Karikó3 l; M# z; D+ a# o1 o- W
3 HPLC Purification of In Vitro Transcribed Long RNA . . . . . . . . . . . . . . . . . . 43
# N& |1 o0 o, \Drew Weissman, Norbert Pardi, Hiro Muramatsu, and Katalin Karikó2 A3 r/ s# o8 K# T8 R: ]5 H. @
4 Synthetic mRNAs with Superior Translation and Stability Properties . . . . . . . . 55/ x( \9 P9 c4 K
Ewa Grudzien-Nogalska, Joanna Kowalska, Wei Su, Andreas N. Kuhn,
* y+ C4 w8 i' U' KSergey V. Slepenkov, Edward Darzynkiewicz, Ugur Sahin, Jacek Jemielity,
( {6 x' }3 I4 wand Robert E. Rhoads
8 X: q4 @! N6 v3 ^" J5 Nonviral, Cationic Lipid-Mediated Delivery of mRNA . . . . . . . . . . . . . . . . . . 73
( C& r  {! w0 yJames G. Hecker
& X, n$ G* w% _" f! y3 q% Y# W6 Light-Induced mRNA Transfection. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89
- P* @1 d7 c8 s$ o* d! d+ rSigurd Leinæs Bøe and Eivind Hovig8 d0 b2 Y5 c6 c3 s1 y" Y
7 Engineering B Cells with mRNA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
( z) I* K0 }4 f4 e; SJaewoo Lee, David Boczkowski, and Smita Nair6 [- Z' t" F: k4 d
8 Programming Human Dendritic Cells with mRNA . . . . . . . . . . . . . . . . . . . . . 111
& E# }  F& u: K  ]Jaewoo Lee, David Boczkowski, and Smita Nair; y8 r$ G3 ]! c
9 Large Volume Flow Electroporation of mRNA: Clinical Scale Process . . . . . . . 1270 }9 H; o% f7 J6 `$ Z
Linhong Li, Cornell Allen, Rama Shivakumar, and Madhusudan V. Peshwa
* X5 x" C+ U; y. F10 Retrovirus-Based mRNA Transfer for Transient Cell Manipulation . . . . . . . . . 139: q, a# u! G/ e; E/ d. O  |, X0 B7 O+ S
Melanie Galla, Axel Schambach, and Christopher Baum' W' d, M& M6 h1 C# k6 R/ ]
11 mRNA Delivery to Human Dendritic Cells by Recombinant Yeast
9 ?0 K! {2 G- C4 d2 Cand Activation of Antigen-Specific Memory T Cells. . . . . . . . . . . . . . . . . . . . . 1637 {- x* b, v, ^" F8 e
Frank Breinig, Tanja Breinig, and Manfred J. Schmitt! f( Z9 o; G" W- b) z% S
PART II MODULATION AND MONITORING OF CELL METABOLISM5 j) y- a% b5 g) F  d3 \! m
12 Nonviral RNA Transfection to Transiently Modify T Cells9 @- ^) f" h8 a1 C- J, ]
with Chimeric Antigen Receptors for Adoptive Therapy . . . . . . . . . . . . . . . . . 187
, f4 i8 F) _! s; c+ NTobias Riet, Astrid Holzinger, Jan Dörrie, Niels Schaft, Gerold Schuler,
0 D3 b, r1 Q9 q) nand Hinrich Abken
0 l, d9 w4 G% P0 k  N/ ?13 Natural Killer Cell Reprogramming with Chimeric Immune Receptors . . . . . . 203* \0 f5 c8 P1 ?0 n+ ]% g' B5 B% q" t
Noriko Shimasaki and Dario Campana
3 K; w% R( d! ?; @/ Z) ~viii Contents
: y8 q3 d2 [. @  j, ~14 Reprogramming to Pluripotency and Differentiation of Cells* I4 n0 A) Y  \. Q3 o
with Synthetic mRNA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 221' z- A9 B" x, O
Peizhe Wang and Jie Na
0 _" x( r- p* [  G8 n$ g15 Antitumor Vaccination with Synthetic mRNA: Strategies for In Vitro
; v' o, ?" t# T2 d) kand In Vivo Preclinical Studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 235
, S  ~1 i/ A6 B7 rMustafa Diken, Sebastian Kreiter, Abderraouf Selmi, Özlem Türeci,
  y5 x% A2 x9 y, X, V* M6 U1 rand Ugur Sahin
% g. n+ H% C& E: F9 I9 W16 Mannosylated and Histidylated LPR Technology for Vaccination
4 Y& f7 \$ I7 P7 swith Tumor Antigen mRNA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 247
' o7 t1 V4 B1 q( {* eChantal Pichon and Patrick Midoux/ r  I, Z& w% C4 k, m
17 Analysis of Survivin-Speci fi c T Cells in Breast Cancer Patients
" H& Q4 l7 f, b2 ^5 J0 v( h8 ~Using Human DCs Engineered with Survivin mRNA . . . . . . . . . . . . . . . . . . . 275
7 I! Z3 g1 s( cÖzcan Met and Inge Marie Svane
- r" ^9 i& F2 M5 `3 |* f# p& E6 r18 mRNA Electroporation as a Tool for Immunomonitoring . . . . . . . . . . . . . . . . 293
6 h, O! h8 p# J7 \7 L: QNathalie Cools, Kirsten Van Camp, Viggo Van Tendeloo, and Zwi Berneman
% a( ~! r2 N& B$ T( L19 mRNA PCR-Based Epitope Chase Method . . . . . . . . . . . . . . . . . . . . . . . . . . . 305" `5 U- e" V- o" l6 q1 W! \' r. R- J
Jean-Daniel Doucet, Dominique Gauchat, and Réjean Lapointe3 g% R3 a0 \) `7 F
Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 321
, T% g+ m# @% o7 C! a. b1 g
6 d, x- ?' A! {* o5 f
) B5 z$ a$ @1 `$ f7 D

dracula8988

顶顶顶

zpj589

give me to see

zpj589

骗人帖子，没有附件

电脑爱好者

能看到吗？

123456zsz

今天没事来逛逛  

txxxtyq

我起来了 哈哈 刚才迷了会  

txxxtyq

天啊. 很好的资源

我心飞翔

原来是这样  

dypnr

照你这么说真的有道理哦 呵呵 不进沙子馁~~~